1632118-70-7

Basic information

• Product Name: BAR 501 impurity
• Synonyms: BAR 501 impurity
• CAS NO: 1632118-70-7
• Molecular Formula: C26H46O3
• Molecular Weight: 406.64164
• EINECS: -0
• Mol File: 1632118-70-7.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BAR 501 impurity(CAS DataBase Reference)
• NIST Chemistry Reference: BAR 501 impurity(1632118-70-7)
• EPA Substance Registry System: BAR 501 impurity(1632118-70-7)

Safety Data

• Hazardous Substances Data: 1632118-70-7(Hazardous Substances Data)

Usage

General Description

BAR 501 impurity is a chemical compound that is used as an intermediate in pharmaceutical manufacturing. It is typically found as an impurity in pharmaceutical products, particularly in the manufacturing of antiretroviral drugs. The presence of BAR 501 impurity in pharmaceutical products must be closely monitored and controlled, as it can potentially affect the safety and efficacy of the final drug product. It is important for pharmaceutical manufacturers to conduct thorough testing and quality control measures to ensure that the levels of BAR 501 impurity are within acceptable limits in their products. Additionally, regulatory agencies such as the FDA and the European Medicines Agency have set guidelines and regulations for BAR 501 impurity levels in pharmaceutical products to ensure patient safety.

Upstream product

• 10452-65-0 methyl 3α-acetoxy-7-oxo-5β-cholan-24-oate 
• 4651-67-6 7-Ketolithocholic acid 
• 10538-59-7 7-ketolithocholic methyl ester 
• 951694-73-8 methyl (4R)-4-((3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate 
• 462122-38-9 3α-hydroxy-6α-ethyl-7-keto-5β-cholanic acid methyl ester 
• 863239-59-2 3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-carboxylic acid methyl ester 

Relevant articles and documents

Synthesis and characterization of new impurities in obeticholic acid

Novel and efficient synthetic strategies are developed for the first synthesis of two new impurities found in obeticholic acid. The synthetic routes to the impurities are designed without column purification using 4-nitrobenzoyl chloride as a selective pr

CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES

13073PTWO 56 ABSTRACT The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases. 5

Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors

Bile acids exert genomic and nongenomic effects by interacting with membrane G-protein-coupled receptors, including the bile acid receptor GP-BAR1, and nuclear receptors, such as the farnesoid X receptor (FXR). These receptors regulate overlapping metabolic functions; thus, GP-BAR1/FXR dual agonists, by enhancing the biological response, represent an innovative strategy for the treatment of enteroendocrine disorders. Here, we report the design, total synthesis, and in vitro/in vivo pharmacological evaluation of a new generation of dual bile acid receptor agonists, with the most potent compound, 19, showing promising pharmacological profiles. We show that compound 19 activates GP-BAR1, FXR, and FXR regulated genes in the liver, increases the intracellular concentration of cAMP, and stimulates the release of the potent insulinotropic hormone GLP-1, resulting in a promising drug candidate for the treatment of metabolic disorders. We also elucidate the binding mode of the most potent dual agonists in the two receptors through a series of computations providing the molecular basis for dual GP-BAR1/FXR agonism.